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ABSTRACT

Objectives: To compare the cost per quality of life (QALY) between immediate
postpartum and interval initiation of intrauterine devices (IUDs) and contraceptive
implants from the societal perspective. Cost per unintended pregnancy prevented
between timing strategies was also compared.
Methods: Two decision analytic models were created using TreeAge Pro 2015 software
for TCu380A IUD and levonorgestrel IUD and for the contraceptive implant. Each
model compared immediate postpartum versus interval contraceptive provision to
determine the occurrence of pregnancy events over time and their impact on costs and
QALYs, using a time horizon of 1 to 5 years. The probabilities of insertion,
expulsion/removal, pregnancy and the utility values with having an unintended
pregnancy were estimated from a literature review. Costs were adjusted to 2014 and
included all direct medical and non-medical expenses such as transportation and infant
care for the first year of life. Indirect costs were estimated using the human capital
method. Sub-analysis using different payer perspectives and adjustments due to
mistimed pregnancies were also done. Univariate and probabilistic sensitivity analyses
(PSAs) were performed to determine robustness of the model.
Results: The strategy of immediate insertion for all three contraceptive devices
dominated interval initiation. For each delivery, interval (versus immediate) insertion
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results in an additional average cost of $1,549, loss of 0.015 QALY, and an additional
incremental cost of $2,249 for each unintended pregnancy prevented. Regardless of
perspective used and after adjustments for mistimed pregnancy, immediate insertion
remains the strategy of choice. Extending the time horizon to 5 years increases the
additional average cost with interval insertion to $2,600, loss of 0.024 QALY, and an
additional incremental cost of $4,923 for each unintended pregnancy prevented. The
models were most sensitive to the probabilities of actual insertion or postpartum loss to
follow up, pregnancy rates from use of IUDs and implants, and cost of immediate
insertion. PSA, using Monte Carlo simulation, show that immediate insertion is less
costly and more effective 95% of the time.
Conclusion: Immediate postpartum IUD and implant initiation is the dominant strategy
compared to interval insertion, which support expansion of long acting reversible
contraception (LARC) coverage.
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Chapter 1
Introduction
Long acting reversible contraception (LARC) includes the intrauterine device
(IUD) and contraceptive implant. The IUD comes in two forms- the copper-containing
Paragard® and the levonorgestrel-containing Mirena® and are prescribed for up to 5-10
years. The implant is marketed as Nexplanon® and is inserted sub-dermally in the upper
arm under local anesthesia. It releases a small continuous amount of the synthetic
progestin etonogestrel and can be left in place for up to 3 years. Both forms of LARC are
highly effective, with failure rates ranging from only 0.05 to 0.8% in the first year of use
(Trussell 2011). Typically, they are inserted at 6 weeks postpartum or at any other time
that a woman is not pregnant. This is called interval insertion. An emerging practice in
the US is to initiate LARC immediately postpartum—at 10 minutes after placental
delivery for the IUD and up to 72 hours after giving birth for the implant. This is called
immediate postpartum insertion.
Despite high efficacy, LARC remains underutilized, with only 8.5% of American
women who are on contraception reporting its use (Finer, Jerman 2012). The relationship
between low LARC utilization rates and unintended pregnancy is well-documented
(Blumenthal, Voedisch 2011, Blumenthal, Shah 2013, Secura 2013). In the United States,
more than half of all pregnancies are unintended, with an estimated annual direct cost of
$4.6 billion (Trussell, Henry 2013).
The immediate postpartum provision of LARC methods has the potential to reduce
the burden of unintended pregnancy. Although postpartum LARC initiation has been is
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commonly used in other parts of the world for the last three decades (Grimes, Lopez 2010)
only a few centers in the US follow this practice.
There are several advantages to the immediate postpartum provision of LARC –
1.) Inadvertent insertion of LARC in pregnant women is avoided, 2.) Women are highly
motivated to initiate birth control use immediately postpartum, and 3.) Provides
convenience for the patient and her provider. However, there are disadvantages as well.
The risk of expulsion for the IUD may be higher for immediate placement and early follow
up is recommended in order to detect this (Grimes, Lopez 2010). IUD expulsion rates are
also dependent on the route of delivery, with cesarean births consistently having lower
expulsion rates than vaginal deliveries (Kapp and Curtis 2009, Mwalwanda and Black
2013). In practice, although an increase in expulsion rate may occur with immediate IUD
insertion, the benefits outweigh this risk given the high rate of no show for the 6-week
postpartum visit.
Systematic reviews have shown that immediate postpartum LARC initiation is
safe and effective (Grimes, Lopez 2010, Kapp and Curtis 2009, Mwalwanda and Black
2013) and provides an opportunity to provide birth control at a convenient time to women
who are highly motivated to prevent subsequent pregnancies. In the classic study by
Echeverri in 1973, of those postpartum women who desired an IUD and had an interval
insertion scheduled, only 45% received their IUD, as compared to 95% of women who
had an IUD placed in the immediate postpartum period (Echeverry 1973). Tocce in 2012
also showed that the uptake and continuation rate of immediate postpartum implants
among adolescents is higher compared to any other form of birth control, including getting
the implant at 6 weeks postpartum (Tocce, Sheeder 2012). Of the identified barriers to
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immediate postpartum LARC use, high upfront cost and insurance coverage relating to
access may be the most prominent. If the financial aspect of procuring contraception was
removed, up to two-thirds of reproductive-aged women would choose LARC (Secura,
Allsworth 2010). Currently, New Mexico is one of only nine states that provide Medicaid
reimbursement for immediate postpartum LARC (ACOG 2014). Among private insurance
companies, only Kaiser Permanente in California recognizes the procedure and provides
coverage.
The American College of Obstetricians and Gynecologists (ACOG) supports the
use of LARC in the immediate postpartum period to aid in reducing unintended pregnancy
rates and rapid repeat pregnancies (ACOG 2009, ACOG 2011). In the state of New
Mexico, about 56% of pregnancies were unintended, with 58% ending in live births (NM
PRAMS 2008). Data from the University of New Mexico Hospital (UNMH) in 2002 show
that about 12% of postpartum women chose interval LARC as their method of birth
control. However, at best, only 60% of these women actually had a LARC placed (Ogburn,
Espey 2005). More recent data from 2006-2011 at UNMH indicate an increasing number
of women who plan to use birth control after delivery, with preference for the implant and
the IUD (Singh, Rogers 2014).
In New Mexico, immediate postpartum LARC insertion is gaining in popularity
and practice, largely because of efforts of providers that resulted in a revision of Medicaid
reimbursement to remove the cost of LARC insertion from the global fee. It is important
to note, however, that even though there is Medicaid coverage that allows and incentivizes
providers to train and perform immediate postpartum LARC, a substantial proportion of
women who deliver in New Mexico are undocumented. These women typically utilize the
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Emergency Medical Services for Aliens (EMSA) program, which is paid for by NM
Medicaid (NM Medical Assistance Program Manual Supplement). EMSA does not
provide coverage for any family planning services, including the immediate postpartum
provision of LARC. In essence, the state pays for the labor and delivery procedures of
undocumented women, with no coverage for birth control.
A cost utility study is a subtype of cost-effectiveness analysis that looks at the cost
per quality of life (QALY) gained. Two previous cost utility analyses of contraceptive
methods show that LARC use leads to cost savings and increased QALYs compared to
methods which require patient adherence such as oral contraceptive pills (Secura 2013,
Sonnenberg, Burkman 2004). A 2015 study of immediate versus interval IUD insertion
by Washington and colleagues demonstrated cost savings of $282,000, 10 additional
QALYS and prevention of 88 unwanted pregnancies for every 1000 women who get
immediate postpartum LARC (Washington, Jamshidi 2015). This study, however, was
done based on a single perspective and did not analyze indirect costs. A study analyzing
the cost effectiveness/cost utility of immediate postpartum IUDs and implants compared
to interval insertion is relevant given the environment and factors discussed above.
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Chapter 2
Specific Aims
Our long-term goal is to increase the practice and uptake of highly effective
contraceptive methods in the US. The overall objective is to perform a cost-utility analysis
of immediate postpartum insertion of LARC methods, specifically the IUD and subdermal implant, compared to interval insertion. The central hypothesis is that immediate
postpartum LARC initiation is more cost-effective. Previous cost effectiveness studies
have shown that LARC use leads to more cost savings (based on societal and
public/private insurer perspectives) and QALYs compared to no contraceptive use or use
of less effective birth control methods such as oral contraceptive pills. If our hypothesis
is proven correct, our results may help to facilitate the national adoption of immediate
postpartum LARC insertion and reduce barriers to coverage and reimbursement.
To test our central hypothesis, we pursued the following objectives using the
societal perspective:
1.

Perform an incremental cost utility analysis (cost per QALY) of immediate

postpartum LARC initiation compared with interval insertion through the creation of a
decision analytic model using a time horizon of 1 year.
2.

Using the same decision analytic model and time horizon of 1 year, perform

secondary analyses on the following:
a. Intermediate outcome - determine the incremental cost per unintended pregnancy
that is prevented when LARC is initiated in the immediate postpartum period versus
interval insertion
b. Perspective – use of hospital and third party payer perspectives
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c. Subgroup analysis based on the characteristics of the postpartum population of
women in the model:
- route of delivery (vaginal versus cesarean)
- age (< 18 y/o and > 18y/o); and
- health insurance status
3. Extension of the time horizon for each decision model to 2, 3, 4 and 5 years.
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Chapter 3
Research Design and Methods
A cost utility analysis is a sub-type of cost effectiveness study which looks at the
costs of two or more strategies (in this case, the timing strategy of immediate postpartum
versus interval LARC) based on a measure of utility. In pharmacoeconomics, utility is a
value between 0 and 1 (zero meaning death and one meaning perfect health) that is
associated with a particular health state and used in the estimation of quality adjusted life
years (QALYs). For example, how do women perceive their quality of life if they have an
unintended pregnancy? What numerical utility value would they equate this to, given that
a value of 1.0 means a “not pregnant” state?
We created two decision analytic models (IUDs and implant) using TreeAge Pro
Computer software that considers women who give birth in New Mexico. We compared
the two strategies of LARC provision (immediate versus interval insertion) in the
postpartum period and determined the occurrences of pregnancy events over time and
their impact on quality of life expressed as QALYs, which is the recommended metric of
health outcomes for cost-effectiveness analysis in health care (Siegel, Torrance 1997).
Figure 1 is the study flowchart depicting how we created, refined and tested our
models, while Figures 2 and 3 show the decision analytic models for postpartum IUD use
and the sub-dermal implant, respectively. Instead of expulsion, removal rates were
incorporated with the model using the implant. The inputs used were derived using three
processes: literature review, database review and inputs from experts within the research
team to generate model parameters based on categories of probabilities, costs and utility
measures for having an unintended pregnancy.
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Collection of information on Immediate postpartum and Interval LARC Use:
Literature Review
Database Review
Interview/Inputs from Experts

Generation of Model Inputs

Figure 1. Study Flowchart. LARC – long acting reversible contraception; QALY – quality adjusted life year;
IUD – intrauterine device.
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Cost, QALY

Pregnancy2
IUD retained

Cost, UIP
prevented
IUD placed
Pregnancy avoided3
Immediate1
Insertion

Pregnancy2
IUD continued
Pregnancy avoided3
Pregnancy2
IUD expelled

Other*
methods4

Pregnancy avoided3
Pregnancy2

IUD discontinued

Implant4
Pregnancy avoided3

Postpartum
women

Pills, patch and
ring4
IUD not placed

Others* - male condoms, diaphragm, withdrawal and NFP
Others† - no method, emergency contraception, sponge, condoms, diaphragm,
withdrawal and NFP

Interval1
Insertion

IUD – intrauterine device; DMPA – deoxymedroxyprogesterone acetate injectable; ABO – abortion;
QALY – quality-adjusted life years; UIP – unintended pregnancy

Decision Analytic Model for the IUD. Time horizon = 1 year.

Figure 2: Decision Analytic Model for the IUD. Time horizon = 1 year. The model starts with IUD use by
postpartum women which then branches out to the two insertion timing strategies. Each strategy were
analyzed using probabilities of uptake, expulsion and pregnancy (failure) rates. The primary endpoint is the
comparison of cost per quality of life (QALY) between immediate and interval insertion. Secondarily, the
cost per unintended pregnancy that is prevented were also computed. Branches with the same numbers lead
to the same pathways, truncated for clarity. For example, pregnancy outcomes follow branching distribution
as seen in #2. (IUD – intrauterine device; Mx – management; UIP – unintended pregnancy).
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Cost, QALY

Pregnancy2
Implant
retained

Cost, UIP
prevented

Implant
inserted
Pregnancy avoided3
Immediate1
Insertion

Implant
removed

Postpartum
women

Other†
methods4
Implant not
placed

IUD4

Pills, patch and
ring4
DMPA4
Interval4
Insertion

Others* - male condoms, diaphragm, withdrawal and NFP
Others† - no method, emergency contraception, sponge, condoms, diaphragm,
withdrawal and NFP

Implant at a
later date4

IUD – intrauterine device; DMPA – deoxymedroxyprogesterone acetate injectable; ABO – abortion;
QALY – quality-adjusted life years; UIP – unintended pregnancy

Figure 3: Decision Analytic Model for the implant. Time horizon = 1 year. The model starts with Implant
use by postpartum
women
which
then branches
Figure 2. Decision Analytic
Model
for the Implant.
Time horizon = out
1 year.to the two insertion timing strategies. Each strategy
were analyzed using the same parameters and output as the IUD, with removal instead of expulsion rates.
Branches with the same numbers lead to the same pathways, truncated for clarity. For example, pregnancy
outcomes follow branching distribution as seen in #2. (IUD – intrauterine device; Mx – management; UIP
– unintended pregnancy).
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The model started with the population of postpartum women who gave birth at the
UNMH from 2010-2012 (average over three years) who were medically eligible to receive
an IUD or implant. These counts were generated through the Clinical and Translational
Science Center (CTSC) data warehouse services based on ICD-9 and CPT codes (see
Appendix). The base case analysis applied to women of average health and fertility,
ranging from 15 to 44 years of age. The models above have been simplified and truncated
for clarity. Some key features of a decision tree:
Square – represents a decision node, typically at the start of a tree that indicates a
decision point between two alternative options (immediate versus interval).
Circle – chance node that shows a point where two or more alternative events for
a patient are possible; these are shown as branches coming out of a node. For example,
after IUD uptake or placement, patients can either retain their IUD or it might fall out.
The sum of the probabilities of each branch from a chance node should equal to one.
Triangle – these are the terminal nodes that represent the end of the pathway.
Moving left to right, the first probabilities in the tree show the probability of an
event happening. Subsequent probabilities are conditional, meaning its probability given
that a previous event has occurred. At the decision node, we are comparing the practice
of immediate postpartum versus interval LARC initiation. For each strategy, a certain
proportion of women will actually have it placed, and among those who had it placed, a
certain number will have their IUDs fall out based on the expulsion rate at 3 months. Some
will choose to have the IUD re-inserted while others switch to other forms of birth control.
Subsequent probabilities are determined by pregnancy or failure rates of each birth control
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methods, as well as the distribution of outcomes of unintended pregnancies (i.e. how many
end up in delivery, induced and spontaneous abortion and ectopic pregnancy).
To explain how the model works, first we determined the cost and utility per
outcome. For example, the total cost for vaginal delivery is $18,511 and the utility of
having an unintended pregnancy and delivering vaginally is 0.88 (a patient who is not
pregnant has a utility of 1.0). We then determined the probability of each branch within a
chance node. For example, 95% of women actually had an IUD placed in the immediate
postpartum period. Of these 95%, 83% retain their IUD while the rest experienced an
expulsion. The probability of getting pregnant while on an IUD is .08% and 56% of these
pregnancies end in deliveries. Among women who deliver, 77% are vaginal deliveries. At
each

terminal

node,

all

of

these

probabilities

were

multiplied

(0.95x0.83X.008x0.56X0.77) to get the total probability of that event happening (i.e. the
event of having an unintended pregnancy that ends in vaginal delivery when an IUD is
retained after immediate postpartum placement). This total probability was multiplied
with the cost ($18,511) and utility (0.88) to get the expected values, and these expected
values were summated per strategy and compared.

Model Structural Assumptions and Parameter Estimates. The following were the
structural assumptions and parameter estimates of the model:
1.

In order to provide a pure comparison, all women within the study population were

assumed to either initiate LARC immediately postpartum or at 6 weeks follow up.
2.

Women who failed to initiate the IUD or implant were assumed to either initiate

use of the combined oral pill/patch/ring, deoxymedroxy progesterone acetate (DMPA)
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injection, other forms of less effective birth control (no method, emergency contraception,
sponge, condoms, diaphragm, withdrawal and natural family planning), or implant or IUD
at a later date based on the frequency distribution of contraceptive use among women
within the reproductive age in the US (Guttmacher Institute Fact Sheet). For women who
have IUD expulsions or implant removals, these probabilities were more favorable
towards birth control use based on published (Singh, Rogers 2014) data since this group
of women are assumed to be more motivated to practice contraception.
3.

The annual probability of unintended pregnancy with IUD or implant use were

based on an average between the lowest and highest failure rates in general from observed
population-based failure rates (Trussell 2011).
4.

Complication and side effects of IUD initiation/use were not included in the model

since it is assumed (based on systematic reviews) that there is no difference in perforation,
infection, pain and bleeding rates between the two timing strategies (Grimes, Lopez 2010,
Kapp and Curtis 2009, Mwalwanda and Black 2013). IUD discontinuation rates were
based on reported spontaneous expulsion rates. Implant removal considered
discontinuation of use from bleeding irregularities and all other causes. Weighted
averages were calculated to determine expulsion and removal rates used in the model.
5.

The range of values that were used in the sensitivity analysis (SA) were either

confidence intervals lifted directly from published studies, set by the research team (which
include a panel of experts), for which a wider range was used, or all probabilities between
0 and 1.
7.

The indirect costs were assumed as the “average” loss of productivity based on

median wage rate, regardless of educational level and socioeconomic status.
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8.

Expansion of the time horizon to 2 to 5 years assumed continued use of the birth

control method women were using at the end of year 1. For the implant, costs were
calculated to reflect removal and re-insertion at the end of year 4.

Model Clinical Inputs: A search strategy guided by a Bioinformatics expert was
employed. The search terms Economics OR Cost and cost analysis AND intrauterine
devices OR desogestrel were applied in the PubMed database, filtered for human studies
and English language (published in LoboVault http://hdl.handle.net/1928/24738).
Additional searches within the Contraception journal and the Guttmacher Institute
literature were also conducted and the reference section of published systematic reviews
were hand-searched for relevant articles. From this, we were able to determine the rates
of actual IUD/implant placement, expulsion/removal rates, percent of women within the
US and New Mexico population using specific methods of birth control, pregnancy rates
within 1 year of birth control use, and the outcomes of unintended pregnancies. Whenever
possible, values specific to probability estimates in New Mexico were used.

Model Cost Inputs: Direct medical costs include those associated with the LARC insertion
itself, including device/drug costs, procedure and follow up costs. Device/drug costs were
based on published average wholesale price (AWP) with adjustments specific to New
Mexico, while procedure costs were based on the Medicare Fee Schedule (Trussell, Henry
2013, Trussell, Lalla 2009). The total initiation costs for contraceptive methods were
calculated from these and include the drug/device, physician consult, insertion, follow up
and removal. Other direct medical cost include the outcomes of unintended pregnancy
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such as the cost of vaginal delivery, cesarean delivery, ectopic pregnancy and induced and
spontaneous abortions and were taken from HealthCare Utilization Project (HCUP.net)
and MEDPAR Inpatient Hospital National Data. Direct non-medical costs include
transportation costs as well as the cost of having an infant during its first year of life.
Indirect costs, which pertain to lost productivity, was estimated using the median hourly
wage in New Mexico with an 18% adjustment on gender gap. These were applied as
opportunity costs on time spent traveling, time spent at the clinic, time spent hospitalized
because of the pregnancy outcome, and time spent on maternity leave. Adjustments for
mistimed pregnancy were also performed separate from the base case analysis.
Calculations were adjusted using medical inflation rates from the Consumer Price Index
and expressed in US 2014 dollars.

Estimating Costs from Different Perspectives. In pharmacoeconomics, the model
perspective defines the costs that are included in the analysis. All direct medical and nonmedical costs (except for transportation) were included in all the perspectives used.
Transportation and indirect costs were estimated specifically for calculating total costs
using the societal perspective.

a. State perspective
In New Mexico, it is estimated that Medicare/Medicaid reimburses approximately
14% less of the published AWP of drug costs and devices (Medicaid.gov 2012).
In terms of procedural costs for the consult, insertion, follow up and removal of
these methods, the previous works of Trussell and colleagues based on the
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Medicare Fee Schedule was utilized for the study models (Trussell, Henry 2013,
Trussell, Lalla 2009).
The average cost of hospitalization for an uncomplicated vaginal and cesarean
delivery, as well as an ectopic pregnancy were lifted directly from the average
Medicaid/Medicare reimbursement rates in 2010 and 2011 (HCUP.net and
MEDPAR database).
Since national inpatient data estimates has a tendency to show skewed abortion
reimbursement costs (i.e. data are overestimated since only the small number of
complicated and life threatening cases of abortion are hospitalized), these costs
(spontaneous and induced) were again estimated from the previous work of
Trussell and colleagues in 2013 (Trussell, Henry 2013). This study assumed more
realistic estimates of about 10% of spontaneous abortions occurring in nonhospital outpatient clinics. Additional data from Jones and colleagues in 2011
allowed us to estimate that only 4% of induced abortions were done in the hospital
setting (Jones and Jerman 2014). Based on the frequency distributions of abortions
occurring in the hospital inpatient, hospital outpatient and non-hospital setting, as
well as the costs reimbursed by Medicare/Medicaid, we calculated the weighted
average costs of abortion procedures.

b. Private Insurance perspective
Commercial insurance costs were estimated based on AWP and differences in
physician reimbursement rates. According to Gencarelli and Goff, private
insurance reimbursement rates of drugs and devices are generally higher than
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public-payer insurance (Goff 2001, Gencarelli 2002). The range is between 2-20%
less than the AWP and for the base case analysis, we used the midpoint of 9%.
In New Mexico, the overall private insurance physician reimbursement rate is 29%
higher than Medicare/Medicaid (US GAO Report 2014). For office
procedures/visits, this difference is about 26%, while it can be as high as 31% for
inpatient procedures. These values were then multiplied with the State costs to
come up with private insurance cost estimates.

c. Hospital perspective
Costs included in analyzing the model from the hospital perspective included the
immediate insertion of the IUDs and implant. Based on data from HCUP.net and
MEDPAR, we estimated that hospitals expend an amount equal to about 26.5% of
public-payer reimbursements related to vaginal and cesarean deliveries. The costs
of immediate LARC insertion were calculated by multiplying this percentage with
the State costs.
Procedure costs for vaginal and cesarean deliveries and ectopic pregnancies were
calculated from the amount not reimbursed by public-payer insurance, again based
on data from HCUP.net and MEDPAR. In cases of spontaneous and induced
abortions, costs were computed based on the percentage of these cases that were
managed in the hospital setting. Due to the lack of published data, we used a
conservative estimate that approximately 50% of the average cost of state
reimbursements both for the medical and surgical management of abortion
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procedures (among the small number of those done in the hospital setting) are
borne by hospitals.

d. Societal perspective
Costs incurred from the societal perspective include all possible medical expenses
that are associated with birth control initiation and pregnancy outcome at a time.
To avoid double counting, these were calculated by summing up private insurance
and hospital costs. The absolute values associated with state cost were already
encompassed in the private insurance costs. Numerically, this is represented by the
following:
Societal Costs = State Costs + (Private insurance cost – State Costs) + Hospital
Costs
Additionally, estimates pertaining to direct non-medical costs (such as
transportation and infant care for the first year of life) and indirect costs were
included in computing the total societal costs.

Model Health Utility Inputs. The utility values that women place when having an
unintended pregnancy were estimated based on studies by Sonnenberg and colleagues in
2004 and Schwarz and colleagues in 2008. The former study estimated it using a
convenience sample of women, and have been referenced to in other cost-utility studies
on LARC (Sonnenberg, Burkman 2004). These values were used in the base case analysis,
since they were also the most conservative. The work of Schwarz and colleagues was
based on a cross sectional sample of women using various methods including the visual
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analog scale (VAS), time trade-off and standard gamble techniques (Schwarz, Smith
2008). The range of values reported from all three techniques were used in the sensitivity
analysis.
The end result compared the cost per quality of life year gained for each
unintended pregnancy avoided between the two timing strategies (i.e. incremental cost
utility ratio). Secondary analysis allowed us to report the incremental cost per unintended
pregnancy that is prevented (incremental cost effectiveness ratio, ICER), as well as
extended the model for up to five years, using an annual discount rate of 3%. Additionally,
the incremental ratios using hospital and third party payer (state-funded and private
insurance) perspectives were determined. The individual values generated from the
models were applied to the population estimates garnered from the CTSC data warehouse
review. The study population was also stratified based on postpartum mode of delivery
(vaginal versus cesarean delivery), patient population age (< 18 y/o and > 18y/o), and
insurance status (state funded, private insurance and self-pay/EMSA).
Sensitivity analyses were performed to test the robustness of the model, again
using TreeAge Pro computer software. Univariate sensitivity analyses on model inputs
were conducted and these include the following: actual IUD/implant insertion rates, IUD
expulsion/implant removal probabilities, QALYs and outcomes and the costs of birth
control initiation and unintended pregnancies. The range of values used were either based
on standard deviations, range of all possible values in literature or set up to +/- 50% of the
mean value. For actual insertion and expulsion/removal rates, all possible values between
0 and 1.0 were used.
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Monte Carlo simulations were also applied to define confidence intervals for the
main outcome (cost per QALY), and to test the “model’s robustness to simultaneous
multivariable changes” (Salcedo, Sorensen 2013). This allowed us to run 10,000
simulations using all the possible combinations of distributions of model parameter
values. The parameters varied in the probabilistic sensitivity analysis (PSA) included
uptake and expulsion rates, IUD/implant continuation after expulsion/removal, pregnancy
rates with IUD/implant use, and the costs of IUD/implant initiation and pregnancy
outcomes. We assumed beta distribution for the clinical parameters and a normal
distribution for the cost parameters, using standard deviations from literature.
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Chapter 4
Results and Data Analysis
Description of study population. From the years 2010-2012, more than ten thousand
women delivered at the University of New Mexico Hospital (UNMH). On average, about
3,239 of these women per year were medically eligible to receive the IUD and
contraceptive implant either immediately after delivery or at six weeks postpartum.
Majority (60%) of these women were Hispanic. Of the non-Hispanic population, 17%
were Whites and 11% were Native Americans. About 92% were older than 18 years of
age. Seventy eight percent (78%) delivered vaginally, while 22% gave birth via cesarean
section. These values closely mirror the state cesarean section rate of 23.3% (Menacker
and Hamilton 2010).
In terms of insurance status, 18% had commercial insurance, 49% relied on a statecovered third party payer, while more than a third (~33%) were uninsured. There were
about 11 prenatal visits per pregnancy while only about 46% had any form of postpartum
follow up. Among these women who had a postpartum visit, the average number is 1.5
per pregnancy.
Tables 1 and 2 show the probabilities for the model clinical parameters. For the
expulsion/removal rates of IUDs and implants at 3 months, we calculated a single value
from the weighted average of expulsion rates of prospective observational and randomized
controlled trials (RCTs) that compare immediate versus interval LARC based on their
sample sizes.
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Table 1. Clinical Inputs for the Decision Analytic Model.
LNG
ENG
TCu380A
Parameter
IUD
implant
Paragard®
Mirena® Nexplanon®
Immediate Insertion actual IUD/implant
0.950
0.950
0.950
placement prior to
discharge
Interval Insertion - actual
IUD/implant placement
0.600
0.600
0.600
on pp follow up
Immediate Insertion IUD expulsion/implant
0.172
0.131
0.211
removal rate (overall)
Immediate insertion IUD expulsion rate
(vaginal delivery)
Immediate insertion IUD expulsion rate (CS)
Interval Insertion - IUD
spontaneous
expulsion/implant
removal rate (overall)
Percent of women who
continued the IUD after
expulsion
After IUD
expulsion/implant
removal - Percent of
women using DMPA pp
After IUD
expulsion/implant
removal - Percent of
women using the
implant/IUD pp
After IUD
expulsion/implant
removal - Percent of
women using PPR pp
After IUD
expulsion/implant
removal - Percent of
women who are using
other* forms of BC pp
Pregnancy rate with IUD
in place
Pregnancy rate with
Other* method of BC
Pregnancy rate with
Other+ method of BC

0.178

-

-

0.126

-

-

0.024

0.024

.247

0.670

0.670

-

0.098

0.098

0.060

0.042

0.042

0.414

Source

(Echeverry 1973)
(Ogburn, Espey 2005)

(Ogburn, Espey 2005)

Weighted average:
TCu380A: (Eroglu, Akkuzu 2006) (Bonilla
Rosales, Aguilar Zamudio 2005, Celen,
Moroy 2004, Feldblum, Caraway 2005,
Morrison, Waszak 1996, Chi, Wilkens
1985, Van Der Pas, Delbeke 1980, Thiery,
van Kets 1982, Lara Ricalde, Menocal
Tobias 2006, Meirik, Rowe 2009, Wu, Hu
2000, Letti Muller, Lopes Ramos 2005,
Zhou and Chi 1991, Lara, Sanchez 1989)
LNG IUD: (Whitaker, Endres 2014,
Dahlke, Terpstra 2011, Chen, Reeves 2010,
Hayes, Cwiak 2007)
ENG implant: (Tocce, Sheeder 2012,
Wilson, Tennant 2014, Darney, Patel 2009)

(Whitaker, Endres 2014, Chen,
Reeves 2010)

(Singh, Rogers 2014): birth control
plan postpartum among a cohort of
NM women
0.538

0.538

0.329

0.322

0.322

0.197

0.008
(year 1)

0.002
(year 15)

-

0.279

0.279

0.279

0.668

0.668

0.668
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(Trussell 2011)
Weighted average: (Trussell 2011,
(Singh, Rogers 2014)
Weighted average: (Trussell 2011,
Guttmacher Institute 2015)

Table 1, Continuation…
Parameter
Pregnancy rate with
implant use
Pregnancy rate with PPR
use
Pregnancy rate with
DMPA use
When IUD/implant not
placed - Percent of
women with other+
forms of BC pp
When IUD/implant not
placed - Percent of
women with
implant/IUD use pp
When IUD/implant not
placed - Percent of
women with pill use pp
When IUD/implant not
placed - Percent of
women with DMPA use
pp
When IUD/implant not
placed - Percent of
women with
IUD/implant at a later
date pp
Percent of UIP ending in
vaginal deliveries
Percent of UIP ending in
CS

TCu380A
Paragard®

LNG
IUD
Mirena®

ENG
implant
Nexplanon®

0.001

0.001

0.0005

0.090

0.090

0.090

0.060

0.060

0.060

0.677

0.677

0.677

0.004

0.004

0.045

0.244

0.244

0.244

0.030

0.030

0.030

0.045

0.045

0.004

0.233

0.233

0.233

0.767

0.767

0.767

Source

(Trussell 2011)

Guttmacher Institute 2015:
prevalence of birth control use in
the US

(Menacker and Hamilton 2010);
rates specific to NM

LNG – levonorgestrel; IUD – intrauterine device; ENG – etonogestrel; CS – cesarean section; pp – postpartum;
DMPA – deoxymedroxy progesterone acetate injectable; PPR – pills, patch, ring; BC – birth control; ABO – abortion;
UIP – unintended pregnancy; Other* - male condoms, diaphragm, withdrawal and natural family planning; Other+ no method, emergency contraception, sponge, condoms, diaphragm, withdrawal and natural family planning; NM –
New Mexico. Highlighted in bold are the rates specific to the levonorgestrel-containing intrauterine device.
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Table 2. Outcomes of unintended pregnancies per birth control method.
Method
Ectopic
Deliveryb
Induced
a
pregnancy
ABOb
TCu380A IUD
0.03
0.56
0.28

Spontaneous
ABOb
0.13

TOTAL
1.00

LNG IUD

0.50

0.29

0.15

0.07

1.00

IUD (combined)

0.27

0.43

0.21

0.10

1.00

Implant

0.01

0.57

0.29

0.13

1.00

PPR

0.01

0.57

0.29

0.13

1.00

DMPA

0.01

0.57

0.29

0.13

1.00

Other*

0.01

0.57

0.29

0.13

1.00

Other+

0.01

0.57

0.29

0.13

1.00

a (Trussell,

Henry 2013)
b Rates were calculated from the estimated outcome of unintended pregnancies in New Mexico: 58% deliveries, 29%
induced abortions and 13% spontaneous abortions (Finer and Kost 2011).
IUD – intrauterine device; LNG – levonorgestrel; PPR – pills, patch, ring; DMPA – deoxymedroxy progesterone
acetate injectable; ABO – abortion; Other* - male condoms, diaphragm, withdrawal and natural family planning;
Other+ - no method, emergency contraception, sponge, condoms, diaphragm, withdrawal and natural family planning.

Table 3 represents the costs for each birth control method by perspective, while Table 4
shows procedural costs involved including physician consult, insertion cost, removal cost
and follow up. The combination of these two tables showing the total initiation costs is
seen in Table 5. The cost per insertion strategy (immediate versus interval) for
IUD/implant initiation is also shown.
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Table 3. Costs of drugs/devices based on perspective.
Birth Control
2014
State
Private
Method
AWP (AWP-14%)a (AWP-9%)b
TCu380A IUD
539.79
571.17
627.66

Hospital
(State x .265)c
143.04

Societal
(Private+hospital)d
714.22

LNG IUD

737.92

634.61

671.51

168.17

839.68

Implant (upfront)

692.13

595.23

629.84

157.74

787.57

Pills, patch, ring
(9 months)
Pills, patch, ring (12
months)
DMPA (9 months)

522.70

449.52

475.66

0.00

475.66

679.51

584.38

618.36

0.00

618.36

176.21

151.54

160.35

0.00

160.35

DMPA (12 months)

234.94

202.05

213.80

0.00

213.80

138.57

119.17

126.10

0.00

126.10

184.75

158.89

168.13

0.00

168.13

17.36

14.93

15.80

0.00

15.80

23.15

19.91

21.07

0.00

21.07

Others* (9 months)

e

Others* (12 months)
Others+ (9 months)

e

f

Others+ (12 months)f

AWP – average wholesale price; IUD – intrauterine device; LNG – levonorgestrel; DMPA – deoxymedroxy
progesterone acetate injectable; Other* - male condoms, diaphragm, withdrawal and natural family planning; Other+ no method, emergency contraception, sponge, condoms, diaphragm, withdrawal and natural family planning.
a

Based on the average wholesale price in New Mexico from the Medicaid Covered Outpatient Prescription Drug
Reimbursement Information by State 2012.
b Private insurance average wholesale price range is between 2-20% less (Goff 2001, Gencarelli 2002); we used the
midpoint which is 9% to estimate how much commercial insurance companies reimburse for the cost of drugs/devices.
c Hospital costs for the intrauterine devices and implants were estimated based on average cost to charge ratios for
vaginal and cesarean delivery for 2014, as a portion of state reimbursement.
d Societal cost represent the total potential expense for each drug/device; state costs are already encompassed within
private costs so they were not added separately to avoid double counting.
e Driven by cost of diaphragm, including fitting and supplies.
f Driven by cost of male condom.
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Table 4. Procedure cost for each contraceptive drug/device by perspective.
Procedure
Method
Statea
Private
Hospital
Costs
(State x 1.26)b (State x .265)c
Consultation TCu380A IUD
72.39
91.21
0.00

Insertion

Removal

Follow up
visit

Societal
(Private + hospital)d
91.21

LNG IUD

72.39

91.21

0.00

91.21

Implant

43.51

54.82

0.00

54.82

Pills, patch, ring

43.51

54.82

0.00

54.82

DMPA

43.51

54.82

0.00

54.82

Others*

29.83

37.58

0.00

37.58

Others+

0.33

0.42

0.00

0.42

TCu380A IUD

75.60

95.26

20.03

115.29

LNG IUD

75.60

95.26

20.03

115.29

Implant

131.59

165.80

34.87

200.67

Pills, patch, ring

0.00

0.00

0.00

0.00

DMPA

0.00

0.00

0.00

0.00

Others*

0.00

0.00

0.00

0.00

Others+

0.00

0.00

0.00

0.00

TCu380A IUD

173.67

218.82

0.00

218.82

LNG IUD

173.67

218.82

0.00

218.82

Implant

194.71

245.34

0.00

245.34

Pills, patch, ring

0.00

0.00

0.00

0.00

DMPA

0.00

0.00

0.00

0.00

Others*

0.00

0.00

0.00

0.00

Others+

0.00

0.00

0.00

0.00

TCu380A IUD

72.39

91.21

0.00

91.21

LNG IUD

72.39

91.21

0.00

91.21

Implant

0.00

0.00

0.00

0.00

Pills, patch, ring

0.00

0.00

0.00

0.00

DMPA

98.59

124.22

0.00

124.22

DMPA
(12 months)
Others*

131.45

165.63

0.00

165.63

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

Others+

IUD – intrauterine device; LNG – levonorgestrel; DMPA – deoxymedroxy progesterone acetate injectable; Other* male condoms, diaphragm, withdrawal and natural family planning; Other+ - no method, emergency contraception,
sponge, condoms, diaphragm, withdrawal and natural family planning.
a

Based on the Medicare fee schedule (Trussell, Henry 2013).
insurance cost in New Mexico is estimated to be 1.26% of the total state reimbursement, based on physician
reimbursement rates of office procedures (US Government Accountability Report 2014).
c Hospital costs for insertion of intrauterine devices and implants were estimated based on average cost to charge ratios
for vaginal and cesarean delivery for 2014, as a portion of state reimbursement.
d Societal cost represent the total potential expense for each procedure; state costs are already encompassed within
private costs so they were not added separately to avoid double counting.
b Private
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Table 5. Initiation costs of birth control methods by perspective.
BC initiation
State
(device/drug,
consult,
insertion)

PI

Hospital

Societal

TCu380A IUD Interval

$687.78

$757.64

$0.00

$757.64

TCu380A IUD Immediate

$615.39

$666.43

$163.08

$829.51

LNG IUD Interval

$782.61

$857.98

$0.00

$857.98

LNG IUD Immediate

$710.21

$766.77

$188.21

$954.97

Implant Interval

$770.32

$850.45

$0.00

$850.45

Implant Immediate

$726.82

$795.64

$192.61

$988.24

Pills, patch, ring

$493.03

$530.48

$0.00

$530.48

DMPA

$195.04

$215.17

$0.00

$215.17

Others*

$149.00

$163.68

$0.00

$163.68

Others+

$15.26

$16.22

$0.00

$16.22

IUD – intrauterine device; LNG – levonorgestrel; DMPA – deoxymedroxy progesterone acetate injectable; Other* male condoms, diaphragm, withdrawal and natural family planning; Other+ - no method, emergency contraception,
sponge, condoms, diaphragm, withdrawal and natural family planning.

Table 6 depicts the procedural costs for each possible outcome of an unintended
pregnancy by perspective. Table 7 shows the prenatal, transportation, infant care and
indirect costs associated with each outcome. These are summarized in Table 8. Finally,
utility values for having an unintended pregnancy are presented in Table 9.

27

Table 6. Procedural costs for outcomes of unintended pregnancies.
Outcome
Vaginal delivery

Procedural Costs 2014

mean hospital charge

$11,620.34

mean hospital cost

$3,425.39

Medicare/Medicaid (State)
Hospital cost

b

Private insurance cost
Societal cost
Cesarean delivery

a

$802.89
c

$3,435.48

d

$4,238.37

mean hospital charge

$19,593.70

mean hospital cost

$5,691.80

Medicare/Medicaid (State)
Hospital cost

a

b

Ectopic pregnancy

$6,089.41

d

$7,132.80

mean hospital charge

$26,678.32

mean hospital cost

$7,395.05

Medicare/Medicaid (State)
Hospital cost
Societal cost
Spontaneous abortion

$5,969.61

d

$8,807.71

b

Private insurance cost
Societal cost

Societal cost

$1,211.82

d

$1,561.79

b

Private insurance cost
d

$939.39
$349.98

c

Medicare/Medicaid (State)
Hospital cost

$4,556.95
$2,838.10

c

Medicare/Medicaid (State)a
Hospital cost

Induced abortion

a

b

Private insurance cost

$4,648.40
$1,043.40

Private insurance cost c
Societal cost

$2,622.51

a

$808.19
$301.19

c

$1,042.57
$1,343.76

Values for mean hospital charge and mean hospital cost were taken from the HealthCare Utilization Project (HCUP.net)
using the diagnosis related group (DRG) specific to the average costs of uncomplicated vaginal delivery (DRG 775),
cesarean delivery (DRG 766) and ectopic pregnancy (DRG 777) for Medicaid patients from 2010-2012.
a

State costs were estimated by multiplying the mean hospital cost to the opportunity cost of the procedure (ratio of
Medicaid reimbursement and covered charges from the MEDPAR Inpatient Hospital National Data).
b Hospital costs were calculated by subtracting the state costs from the mean hospital costs.
c Private insurance costs were calculated by multiplying the state costs by 1.31, estimated from the difference in
physician reimbursements between Medicaid/Medicare and commercial insurance in New Mexico for inpatient
procedures (US Government Accountability Report 2014).
d Societal cost represent the total potential expense for each procedure; calculated from the sum of private insurance and
hospital costs; state costs are already encompassed within private costs so they were not added separately to avoid
double counting.
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Table 7: Prenatal Care, Direct non-medical and Indirect costs by perspective
Privatee
Direct non-medical costs and prenatal
2014
State
care
Transportationa
Two-way
21.20
0.00
0.00
Prenatal care

b

Infant Carec

Vaginal and CS
delivery
Adjusted for
mistimed pregnancyd
Vaginal and CS
delivery

Traveling

Time spent at
Clinic
UIP Outcome
based on average
length of stay
(LOS): wage lost

Maternity Leaveh

Societal

0.00

21.20

2,585.03

2,585.03

3,334.69

0.00

3,334.69

-

1,123.04

1,448.73

0.00

1,448.73

6,956.39

6,956.39

8,973.74

0.00

8,973.74

-

3,022.15

3,898.57

0.00

3,898.57

2014

State

Private

Hospital

Societal

9.03

0.00

0.00

0.00

9.03

12.54

0.00

0.00

0.00

12.54

Vaginal delivery: 2.1
LOS (16.8 hours)g

210.67

0.00

0.00

0.00

210.67

Cesarean delivery:
3.1 LOS (24.8
hours)g
Abortion: 1.5 LOS
(12 hours)g
Ectopic: 1.7 LOS
(13.6 hours)g
Vaginal delivery: 2
weeks (112 hours)g

310.99

0.00

0.00

0.00

310.99

150.48

0.00

0.00

0.00

150.48

170.54

0.00

0.00

0.00

170.54

1,404.48

0.00

0.00

0.00

1,404.48

610.17

0.00

0.00

0.00

610.17

2,808.96

0.00

0.00

0.00

2,808.96

1,220.33

0.00

0.00

0.00

1,220.33

Adjusted for
mistimed pregnancy
Indirect costs (wage lost)
f

Hospital

0.72 hour (43.2
minutes)
1 hour

Adjusted for
mistimed pregnancy
Cesarean delivery: 4
weeks (224 hours)g
Adjusted for
mistimed pregnancy
CS – cesarean section; LOS – length of hospital stay
a

From CNT.org and Oakridge National Lab; total driving cost for New Mexico/#miles = $.50/mile; average of 22 miles
(one way) for medical/dental procedures
b (Monea and Thomas 2011)
c (Rohde 2012)
d Trussell 2009; assuming 60% of unintended pregnancies are actually mistimed with a 3% discount rate in 2 years,
using the formula: cost*[1-(0.6/(1.03)^2)].
e Private insurance costs calculated by multiplying state costs by 129%, estimated from the overall difference in
physician reimbursements between Medicaid/Medicare and commercial insurance in New Mexico (US Government
Accountability Report 2014).
f Indirect cost for traveling estimated from average time to get to work, 21.6 minutes one way in New Mexico (US
Census.gov).
g Indirect costs calculations based on an 8-hour work day.
h Women's Health USA 2011
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Table 8. Total costs for each unintended pregnancy outcome based on perspective.
Societal Perspective
Vaginal delivery
21.20

21.20

21.20

21.20

Spontaneous
ABO
21.20

Prenatal care

3,334.69

3,334.69

0.00

0.00

0.00

Procedure

4,238.37

7,132.80

8,807.71

1,343.76

1,561.79

Infant Care

8,973.74

8,973.74

0.00

0.00

0.00

9.03

9.03

9.03

9.03

9.03

210.67

310.99

170.54

150.48

150.48

Indirect-Maternity Leave

1,722.81

3,445.62

0.00

0.00

0.00

TOTAL

18,510.51

23,228.07

9,008.48

1,524.47

1,742.50

Vaginal delivery

CS delivery

Ectopic

Induced ABO

0.00

0.00

0.00

0.00

Spontaneous
ABO
0.00

Prenatal care

2,585.03

2,585.03

0.00

0.00

0.00

Procedure

2,622.51

4,648.40

4,556.95

808.19

939.39

Infant Care

6,956.39

6,956.39

0.00

0.00

0.00

Indirect-Travel

0.00

0.00

0.00

0.00

0.00

Indirect-LOS

0.00

0.00

0.00

0.00

0.00

Transportation

Indirect-Travel
Indirect-LOS

CS delivery

Ectopic

Induced ABO

State Perspective

Transportation

Indirect-Maternity Leave

0.00

0.00

0.00

0.00

0.00

12,163.93

14,189.82

4,556.95

808.19

939.39

Vaginal delivery

CS delivery

Ectopic

Induced ABO

0.00

0.00

0.00

0.00

Spontaneous
ABO
0.00

Prenatal care

3,334.69

3,334.69

0.00

0.00

0.00

Procedure

3,435.48

6,089.41

5969.61

1,042.57

1,211.82

Infant Care

8,973.74

8,973.74

0.00

0.00

0.00

Indirect-Travel

0.00

0.00

0.00

0.00

0.00

Indirect-LOS

0.00

0.00

0.00

0.00

0.00

Indirect-Maternity Leave

0.00

0.00

0.00

0.00

0.00

15,743.91

18,397.83

5,969.61

1,042.57

1,211.82

TOTAL

Private Insurance Perspective

Transportation

TOTAL

LOS – length of hospital stay; ABO – abortion.
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Table 8, Continuation…
Hospital Perspective
Vaginal delivery

CS delivery

Ectopic

Induced ABO

Transportation

0.00

0.00

0.00

0.00

Spontaneous
ABO
0.00

Prenatal care

0.00

0.00

0.00

0.00

0.00

Procedure

802.89

1,043.40

2,838.10

301.19

349.99

Infant Care

0.00

0.00

0.00

0.00

0.00

Indirect-Travel

0.00

0.00

0.00

0.00

0.00

Indirect-LOS

0.00

0.00

0.00

0.00

0.00

Indirect-Maternity Leave

0.00

0.00

0.00

0.00

0.00

802.89

1,043.40

2,838.10

301.19

349.98

TOTAL

LOS – length of hospital stay; ABO – abortion.

Table 9. Utility values of outcomes of unintended pregnancies.
Parameter
Condition
Values used in Base case
analysisa
Unintended
Not pregnant
1.000
pregnancy
Vaginal delivery
0.879
outcome
Cesarean delivery
0.847

a

Range used in Sensitivity
analysisb
0.487 - 0.997
0.487 - 0.997

Spontaneous abortion

0.942

0.487 - 0.997

Induced abortion

0.962

0.487 - 0.997

Ectopic Pregnancy

0.917

0.487 - 0.997

(Sonnenberg, Burkman 2004); b (Schwarz, Smith 2008)

Base case analysis. Results of the base case analysis using the societal perspective show
that the strategy of immediate LARC insertion dominated interval initiation. Immediate
LARC insertion is less costly and more effective. For each delivery/postpartum woman,
interval (versus immediate) insertion results in an additional average marginal cost of
$1,549, loss of 0.015 QALY, and an additional incremental cost of $2,249 for each
unintended pregnancy prevented (Tables 10 and 11).
The total costs for the entire population of women who delivered, calculated based
on the average number of women who were eligible to receive LARC at both timing
insertion strategies, are also shown in Tables 10 and 11. If we consider this total
population of postpartum women in NM, immediate LARC insertion is associated with
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cost savings of $4.5M to $5.6M, additional QALYs of 45-52, and prevention of 506 to
552 unintended pregnancies per year.

Table 10. Summary of costs and QALYs gained per LARC insertion strategy.
TCu380A IUD
Immediate Insertion
No. of deliveries
eligible
2010-2012
N = 3226/year

$1,495.87

$3,006.67

QALY (per case)

0.996

0.982

Cost/QALY (per case)

$1,501.88

$3,061.78

Marginal Cost/QALY (per case)

-$1,559.90

Total Costs

$4,825,676.62

Marginal Total Costs

-$4,873,840.80

Total QALYs gained

3213

Marginal Total QALYs gained

45

Marginal Total Cost/QALY gained

-$107,914.29

LNG IUD
No. of deliveries
eligible
2010-2012
N = 3222/year

$9,699,517.42
3168

Immediate Insertion

Interval Insertion

Cost (per case)

$1,606.52

$3,023.92

QALY (per case)

0.997

0.982

Cost/QALY (per case)

$1,611.35

$3,079.35

Marginal Cost/QALY (per case)

-$1,467.99

Total Costs

$5,176,207.44

Marginal Total Costs

-$4,566,862.80

Total QALYs gained

3212

Marginal Total QALYs gained

48

Marginal Total Cost/QALY gained

-$94,493.33

ENG implant
No. of deliveries
eligible
2010-2012
N = 3267/year

Interval Insertion

Cost (per case)

$9,743,070.24
3164

Immediate Insertion

Interval Insertion

Cost (per case)

$1,488.33

$3,206.90

QALY (per case)

0.997

0.981

Cost/QALY (per case)

$1,492.81

$3,269.01

Marginal Cost/QALY (per case)

-$1,776.20

Total Costs

$4,862,374.11

Marginal Total Costs

-$5,614,568.19

Total QALYs gained

3257

Marginal Total QALYs gained

52

Marginal Total Cost/QALY gained

-$107,410.63

$10,476,942.30
3205

LNG – levonorgestrel; IUD – intrauterine device; ENG – etonogestrel; QALY – quality adjusted life year.
Total values for costs and quality adjusted life years were calculated from the average total number of women who
delivered at the UNMH from 2010-2012 who were medically eligible to receive the IUD or the implant on either
insertion strategy.
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Table 11. Summary of costs and unintended pregnancies per LARC insertion strategy.
TCu380A IUD
Immediate Insertion
No. of deliveries
eligible
2010-2012
N = 3226/year

Cost (per case)

$1,495.87

$3,006.67

0.961

0.804

Cost/UIP prevented (per case)

$1,556.58

$3,739.64

Marginal Cost/UIP prevented (per
case)
Total Costs

-$2,183.06
$4,825,676.62

Marginal Total Costs

-$4,873,840.80

Total UIP prevented

3100

Marginal Total UIP prevented

506

UIP prevented (per case)

LNG IUD
No. of deliveries
eligible
2010-2012
N = 3222/year

$9,699,517.42
2594

Immediate Insertion

Interval Insertion

$1,606.52

$3,023.92

0.965

0.808

Cost/UIP prevented (per case)

$1,664.79

$3,742.48

Marginal Cost/UIP prevented (per
case)
Total Costs

-$2,077.69
$5,176,207.44

Marginal Total Costs

-$4,566,862.80

Total UIP prevented

3109

Marginal Total UIP prevented

506

Cost (per case)
UIP prevented (per case)

ENG implant
No. of deliveries
eligible
2010-2012
N = 3267/year

Interval Insertion

$9,743,070.24
2603

Immediate Insertion

Interval Insertion

$1,488.33

$3,206.90

0.965

0.796

Cost/UIP prevented (per case)

$1,542.31

$4,028.77

Marginal Cost/UIP prevented (per
case)
Total Costs

-$2,486.46
$4,862,374.11

Marginal Total Costs

-$5,614,568.19

Total UIP prevented

3153

Marginal Total UIP prevented

552

Cost (per case)
UIP prevented (per case)

$10,476,942.30
2601

LNG – levonorgestrel; IUD – intrauterine device; ENG – etonogestrel; UIP – unintended pregnancy.
Total values for costs and number of unintended pregnancies prevented were calculated from the average total number
of women who delivered at the UNMH from 2010-2012 who were medically eligible to receive the IUD or the implant
on either insertion strategy.

Cost perspectives. The costs per QALY gained and unintended pregnancy prevented were
also calculated using different perspectives (Table 12). As expected, the third party payer
perspectives (both state and private insurance) parallel the base case result and show
immediate LARC initiation as the dominant (less costly, more effective) strategy. Based
on the hospital perspective, on the other hand, immediate LARC is still more effective,
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but also more costly. In terms of QALYs, the incremental cost effectiveness ratio (ICER)
ranges from $3,586 to $5,255, which is way below the usual willingness to pay (WTP)
threshold of $50,000. The ICER in terms of unintended pregnancy prevented is even
lower, with a range of $333 to $489.

Table 12. Summary of marginal cost effectiveness results based on different perspectives.
STATE
TCu380A IUD

LNG IUD

ENG implant

COST

QALY

UIP Prevented

Interval

$2,033.91

0.982

0.804

Immediate

$1,049.94

0.996

0.961

Marginal Cost/Effectiveness

-$983.97

0.014

0.157

Interval

$2,063.69

0.982

0.808

Immediate

$1,143.51

0.997

0.965

Marginal Cost/Effectiveness

-$920.18

0.015

0.157

Interval

$2,204.96

0.981

0.796

Immediate

$1,062.47

0.997

0.965

Marginal Cost/Effectiveness

-$1,142.49

0.016

0.169

COST

QALY

UIP Prevented

Interval

$2,601.59

0.982

0.804

Immediate

$1,264.69

0.996

0.961

Marginal Cost/Effectiveness

-$1,336.90

0.014

0.157

Interval

$2,589.73

0.982

0.808

Immediate

$1,329.11

0.997

0.965

Marginal Cost/Effectiveness

-$1,260.62

0.015

0.157

Interval

$2,735.42

0.981

0.796

Immediate

$1,221.81

0.997

0.965

Marginal Cost/Effectiveness

-$1,513.61

0.016

0.169

PRIVATE
TCu380A IUD

LNG IUD

ENG implant

LNG – levonorgestrel; IUD – intrauterine device; ENG – etonogestrel; UIP – unintended pregnancy; QALY – quality
adjusted life year; ICER – incremental cost effectiveness ratio.
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Table 12, Continuation…
HOSPITAL
TCu380A IUD

COST

QALY

UIP Prevented

Interval

$128.15

0.982

0.804

Immediate

$180.55

0.996

0.961

Incremental

$52.40

0.014

0.157

$3,586.10

$333.46

Cost/Effectiveness
ICER
LNG IUD

Interval

$126.86

0.982

0.808

Immediate

$203.64

0.997

0.965

Incremental

$76.78

0.015

0.157

$5,254.87

$488.71

Cost/Effectiveness
ICER
ENG implant

Interval

$133.52

0.981

0.796

Immediate

$206.29

0.997

0.965

Incremental

$72.77

0.016

0.169

$4,641.06

$431.54

Cost/Effectiveness
ICER

LNG – levonorgestrel; IUD – intrauterine device; ENG – etonogestrel; UIP – unintended pregnancy; QALY – quality
adjusted life year; ICER – incremental cost effectiveness ratio.

Sub-group analyses.
1. Route of delivery - The rate of TCu380A expulsion when placed immediately has
been reported to be increased in women delivering vaginally (Lara Ricalde, Menocal
Tobias 2006, Zhou and Chi 1991, Lara, Sanchez 1989). In using weighted averages, the
expulsion rate for immediate TCu380A insertion is 0.178 for vaginal deliveries, compared
to 0.126 in cesarean sections. Adoption of the base case result to the total number of
women who delivered vaginally in the study population shows that, even with this
expulsion rate, immediate postpartum copper IUD leads to potential total cost savings of
$3.7M, additional QALYs of 35, and prevention of 395 unintended pregnancies per year.
2.

Adolescent population – As of early 2015, NM has one of the highest teenage

pregnancy rate in the US. When the base case result is applied to the 8% of women who
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deliver that are 18 years or younger, implementing immediate postpartum LARC is
associated with total cost savings of $401,463, additional QALYs of 4, and prevention of
42 unintended pregnancies per year.
3. Private insurance – At present, almost all commercial insurance companies
provide no coverage of immediate postpartum LARC insertion. Again, when the base case
result is applied to the approximately 18% of women who deliver with private insurance,
immediate LARC initiation can lead to total cost savings of $799,153, additional QALYs
of 9, and prevention of 94 unintended pregnancies per year.
4. Uninsured women – As mentioned above, labor and delivery of women with no
insurance are covered by EMSA, which is a state funded program. Coverage of the
initiation of LARC immediate after delivery can lead to total cost savings of $1M,
additional QALYs of 16, and prevention of 172 unintended pregnancies per year.
Time horizon. The base case analysis apply to a time horizon of 1 year. Extending the time
horizon increases the potential cost savings, gains in QALY and prevention of unintended
pregnancy. With a time horizon of 5 years, for each delivery, interval (versus immediate)
insertion results in an additional average incremental cost of $2,600, loss of 0.024 QALY,
and an additional incremental cost of $4,923 for each unintended pregnancy prevented
(Table 13).
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Table 13. Summary of marginal cost effectiveness results based on different time horizons.
YEAR 2
COST
QALY
UIP Prevented
TCu380A IUD

LNG IUD

ENG implant

Interval

$3,919.49

0.975

0.731

Immediate

$1,758.07

0.995

0.941

Marginal Cost/Effectiveness

-$2,161.42

0.020

0.210

Interval

$3,906.90

0.976

0.737

Immediate

$1,845.69

0.995

0.947

Marginal Cost/Effectiveness

-$2,061.21

0.019

0.210

Interval

$4,231.55

0.974

0.716

Immediate

$1,734.26

0.995

0.947

Marginal Cost/Effectiveness

-$2,497.29

0.021

0.231

COST

QALY

UIP Prevented

Interval

$4,321.77

0.972

0.700

Immediate

$1,917.97

0.993

0.929

Marginal Cost/Effectiveness

-$2,403.80

0.021

0.229

Interval

$4,294.05

0.973

0.708

Immediate

$1,999.95

0.994

0.936

Marginal Cost/Effectiveness

-$2,294.10

0.021

0.228

Interval

$4,730.84

0.970

0.679

Immediate

$1,892.15

0.994

0.935

Marginal Cost/Effectiveness

-$2,838.69

0.024

0.256

COST

QALY

UIP Prevented

Interval

$4,540.97

0.971

0.685

Immediate

$2,024.68

0.993

0.922

Marginal Cost/Effectiveness

-$2,516.29

0.022

0.237

Interval

$4,511.82

0.971

0.692

Immediate

$2,118.45

0.993

0.927

Marginal Cost/Effectiveness

-$2,393.37

0.022

0.235

Interval

$5,508.61

0.968

0.658

Immediate

$2,868.02

0.993

0.927

Marginal Cost/Effectiveness

-$2,640.59

0.025

0.269

YEAR 3
TCu380A IUD

LNG IUD

ENG implant

YEAR 4
TCu380A IUD

LNG IUD

ENG implant

LNG – levonorgestrel; IUD – intrauterine device; ENG – etonogestrel; UIP – unintended pregnancy; QALY – quality
adjusted life year.
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Table 13, Continuation…
YEAR 5
TCu380A IUD

LNG IUD

ENG implant

COST

QALY

UIP Prevented

Interval

$4,686.96

0.970

0.675

Immediate

$2,100.22

0.992

0.916

Marginal Cost/Effectiveness

-$2,586.74

0.022

0.241

Interval

$4,662.80

0.970

0.682

Immediate

$2,212.26

0.993

0.920

Marginal Cost/Effectiveness

-$2,450.54

0.023

0.238

Interval

$5,723.74

0.967

0.643

Immediate

$2,961.50

0.993

0.921

Marginal Cost/Effectiveness

-$2,762.24

0.026

0.278

LNG – levonorgestrel; IUD – intrauterine device; ENG – etonogestrel; UIP – unintended pregnancy; QALY – quality
adjusted life year.

Adjustment for mistimed pregnancies. Many unplanned pregnancies occur in women who
desire a future pregnancy at another time in their lives and these pregnancies are
considered to be mistimed. This means that these pregnancies would have still occurred,
but at a later date. Assuming that 60% of unintended pregnancies are actually mistimed
and would occur two years later, we adjusted the costs of vaginal and cesarean deliveries,
as well as the costs of prenatal care, infant care for the first year of life and indirect costs
related to delivery and maternity leave. Table 14 shows the summary of marginal costeffectiveness using an annual discount rate of 3%. Even with these adjustments, the results
of the base case both for year 1 and year 2 (i.e. immediate LARC insertion is the dominant
strategy) are maintained.
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Table 14. Marginal cost effectiveness when societal costs are adjusted for mistimed pregnancy.
TCu380A
Cost
QALY
UIP prevented
IUD
Year 1 Interval
$1,757.50
0.982
0.804

Year 2

Immediate

$1,249.58

0.996

0.961

Marginal cost effectiveness

-$507.92

0.014

0.157

Interval

$2,219.20

0.975

0.731

Immediate

$1,387.91

0.995

0.941

Marginal cost effectiveness

-$831.29

0.020

0.210

Cost

QALY

UIP prevented

Interval

$1,801.46

0.982

0.808

Immediate

$1,388.19

0.997

0.965

Marginal cost effectiveness

-$413.27

0.015

0.157

Interval

$2,251.64

0.976

0.737

Immediate

$1,521.75

0.995

0.947

Marginal cost effectiveness

-$729.89

0.019

0.210

Cost

QALY

UIP prevented

Interval

$1,905.00

0.981

0.796

Immediate

$1,262.55

0.997

0.965

Marginal cost effectiveness

-$642.45

0.016

0.169

Interval

$2,436.88

0.974

0.716

Immediate

$1,397.54

0.995

0.947

Marginal cost effectiveness

-$1,039.34

0.021

0.231

LNG IUD
Year 1

Year 2

ENG
implant

Year 1

Year 2

LNG – levonorgestrel; IUD – intrauterine device; ENG – etonogestrel; UIP – unintended pregnancy; QALY – quality
adjusted life year.

One way sensitivity analyses (SA). Table 15 gives the summary of the threshold values of
the different parameters in the model. The model is sensitive to the rates of actual LARC
placement, pregnancy rates from use of IUDs, implants and other forms of birth control
methods (as a group) that women use when the IUD/implant is not placed, the cost of
immediate LARC insertion and the utility of avoiding an unintended pregnancy. In table
15, immediate IUD/implant insertion is less costly and more effective compared to
interval insertion as long as the actual rate of immediate insertion is at least 60% and when
the actual rate of interval insertion is less than 90%. Immediate LARC is also dominant
when the pregnancy rate from IUD/implant use not greater than 40%, and when the
pregnancy rate from other methods (when it is not placed) is greater than 3 to 10%.
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Interval insertion becomes the dominant strategy only when the cost of immediate LARC
insertion exceeds $3,000 in terms of QALYs and exceeds $10,000 in terms of unintended
pregnancies prevented.

Table 15. One way sensitivity analysis: threshold values of parameters that affect cost effectiveness results.
Model Parameter
TCu380A
LNG IUD
ENG implant

Actual IUD/implant
placement at interval
insertion
Actual IUD/implant
placement at immediate
insertion
Pregnancy rate IUD/implant use
Pregnancy rate - use of
Other+ forms of birth
control
Cost of immediate
IUD/implant insertion
Utility of avoiding an
unintended pregnancy

QALY

UIP
prevented

QALY

UIP
prevented

QALY

UIP
prevented

0.918

0.932

0.905

0.926

0.976

0.973

0.621

0.612

0.630

0.616

0.584

0.586

0.482

0.538

0.529

0.563

0.404

0.440

0.100

0.030

0.124

0.036

0.034

no effect

$3,188.86

$10,690.29

$3,215.99

$10,715.99

$3,622.53

$11,672.76

0.715

-

0.727

-

0.703

-

LNG – levonorgestrel; IUD – intrauterine device; ENG – etonogestrel; UIP – unintended pregnancy; QALY – quality
adjusted life year

Probabilistic sensitivity analyses (PSA). Monte Carlo simulation using 10,000 iterations
was employed in evaluating the decision analytic model. It allowed us to test the
robustness of the model because values of different parameters were sampled many times
over based on their statistical distributions. Table 16 gives a summary of the results. PSA
showed that all three models demonstrate the dominance of immediate LARC over
interval insertion 95% of the time. The average cost and effectiveness for each LARC
method, as well their standard deviations, are also shown.
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Table 16. Summary of probabilistic sensitivity analysis results
Immediate LARC
dominates
Interval LARC
(% of the time)

TCu380A
IUD

LNG IUD

ENG implant

QALY

0.9451

UIP
Prevented

0.9544

QALY

0.9376

UIP
Prevented

0.9516

QALY

0.9705

UIP
Prevented

0.9720

Average
Costs

SD

Average
E

SD

Interval

$3,001.78

1,184.77

0.935

0.038

Immediate

$1,498.76

555.19

0.987

0.018

Interval

$3,005.67

1,180.83

0.804

0.104

Immediate

$1,491.15

523.50

0.962

0.050

Interval

$3,018.71

1,185.97

0.936

0.039

Immediate

$1,603.44

520.46

0.988

0.017

Interval

$3,017.34

1,195.05

0.808

0.106

Immediate

$1,609.49

534.06

0.965

0.051

Interval

$3,203.27

1,161.49

0.932

0.038

Immediate

$1,481.81

512.16

0.988

0.017

Interval

$3,205.85

1,161.67

0.796

0.103

Immediate

$1,486.91

545.90

0.964

0.051

LNG – levonorgestrel; IUD – intrauterine device; ENG – etonogestrel; UIP – unintended pregnancy; QALY – quality
adjusted life year; E – effectiveness; SD – standard deviation

Figures 4 to 9 show the cost-effectiveness scatter plots for each LARC method in
terms of QALYs and unintended pregnancies prevented. These graphs provide a pictorial
representation of cost and effectiveness when the model was run 10,000 times, based on
the distribution of all possible values of the model parameters. Majority of the points are
seen in the left upper quadrant, showing that interval insertion is both more costly and less
effective compared to immediate insertion. The ellipses show the 95% confidence
interval, meaning that we are confident that cost-effectiveness results would fall on this
area 95% of the time.
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Figure 4. Incremental cost-effectiveness scatterplot for the TCu380A IUD with effectiveness expressed as
quality adjusted life years (QALYs). IUD – intrauterine device.

Figure 5. Incremental cost-effectiveness scatterplot for the TCu380A IUD with effectiveness expressed as
unintended pregnancies (UIP) prevented. IUD – intrauterine device.
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Figure 6. Incremental cost-effectiveness scatterplot for the levonorgestrel (LNG) IUD with effectiveness
expressed as quality adjusted life years (QALYs). IUD – intrauterine device.

Figure 7. Incremental cost-effectiveness scatterplot for the levonorgestrel (LNG) IUD with effectiveness
expressed as unintended pregnancies (UIP) prevented. IUD – intrauterine device.
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Figure 8. Incremental cost-effectiveness scatterplot for the etonogestrel (ENG) implant with effectiveness
expressed as quality adjusted life years (QALYs).

Figure 9. Incremental cost-effectiveness scatterplot for the etonogestrel (ENG) implant with effectiveness
expressed as unintended pregnancies (UIP) prevented.
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Chapter 5
Discussion
Long acting reversible contraceptive methods such as the IUD and implant have
been shown to be cost-effective healthcare interventions that lead to the prevention of
unintended pregnancies. Although unintended pregnancies cause substantial distress to
women, very few studies have conducted economic analyses that looked at its impact on
quality of life. A quality adjusted life year (QALY), which represents a year in perfect
health, is the recommended metric of health outcomes for cost-effectiveness analysis in
health care (Siegel, Torrance 1997). Using this cost-utility approach demonstrated through
modeling that immediate postpartum LARC is beneficial to women and to the society as
a whole.

Base case analysis: QALYs and Unintended pregnancies prevented
The base case analysis show that immediate postpartum LARC is both less costly
and more effective compared to interval insertion. This supports previous findings that
IUDs and implants are cost effective. Previous studies have shown that LARC use is the
strategy of choice when compared to no method use and when compared to other userdependent methods of birth control. One study by Washington and colleagues in 2015
compared timing of insertion strategies for the IUD, and demonstrated that immediate
initiation is less costly and more effective compared to interval insertion (Washington,
Jamshidi 2015).
This present analysis is unique in using the societal perspective. This takes into
consideration indirect costs, which relates to the lost in productivity when women have
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unintended pregnancies. Results of this study indicate that indirect costs contribute up to
12% of the additional costs associated when providing LARC at 6 weeks post-delivery
compared to immediate insertion. Indirect costs were estimated from potential lost wages
using the usual 8-hour work day, and therefore could actually be higher, had we placed a
value on lost productivity based on a 24-hour period.
Trussell and colleagues estimate that about 60% of unintended pregnancies are
actually mistimed, based on the National Survey of Family Growth (NSFG) (Trussell,
Lalla 2009). Mistimed pregnancies are not entirely avoidable when calculating costs, since
they are postulated to occur at a later date. Even when adjustments for mistimed
pregnancies were applied to the base case analysis, the additional costs still exceed those
of previous studies. This underlines the contribution of indirect costs in estimating the
total burden of having an unintended pregnancy.

Analysis using different payer perspectives
Analysis of the models using different payer perspectives also support the base
case results. Third party payer perspectives, both state and commercially funded, show
dominance of immediate LARC insertion in terms of QALYs and unintended pregnancies
prevented. Cost savings were higher using the private insurance perspective mainly
because of higher reimbursement rates. In New Mexico, the average provider
reimbursement is 29% higher with commercial insurance plans compared to
Medicare/Medicaid. Average wholesale prices of drugs and devices can also be higher
with private insurance by as much as 12%, compared to state-funded insurance.
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The hospital perspective shows that immediate LARC insertion is more effective
but more costly than interval initiation. It shows an ICER of less than $5,000 per QALY
and less than $500 for each unintended pregnancy prevented. These values are way below
the usual willingness to pay threshold in pharmacoeconomics set at $50,000 per QALY.
Essentially, if an intervention gives an incremental ratio of less than this threshold, then it
is an acceptable strategy of choice.

Sub-analysis based on postpartum population
Immediate postpartum LARC still dominates interval insertion even if the model
was applied to the adolescent population. The same holds true when we stratify the
postpartum population based on route of delivery. Despite increased IUD expulsion rates
with vaginal delivery (versus cesarean section), immediate postpartum LARC remains
less costly and more effective both in terms of QALYs and the number of unintended
pregnancies prevented.

Time horizon
The decision model in the study used a time horizon of 1 year. Extending this
time period to 5 years shows consistent increase in the cost-effectiveness of immediate
postpartum LARC. The high upfront costs of LARC is negated given the low failure rates,
with associated decrease in unintended pregnancies and increase in quality of life.
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Sensitivity Analyses
LARC methods are cost-effective because of high compliance and continuation
rates (Mavranezouli 2009). In previous studies, the rate of expulsion with immediate
insertion has been a concern, with recommendations supporting LARC use as long as it is
less than 54% (Washington, Jamshidi 2015). In the present study, the rates of expulsion
had no effect on the relative cost effectiveness of immediate postpartum LARC compared
to interval LARC.
Results of the one way SA show that the models were most sensitive to the actual
placement of LARC in the immediate postpartum versus the interval 6 week period.
Immediate postpartum LARC remains dominant as long as actual insertion rates are
greater than 60%. Only when the follow up rate (and actual insertion) of interval LARC
is at least 90%, then it becomes the dominant strategy. In our models, we assumed a 95%
rate of actual placement for immediate insertion and 60% for interval insertion, based on
the previous works in literature ((Echeverry 1973, Ogburn, Espey 2005)
Results were also sensitive to the pregnancy rates with the IUD or implant in place.
In the models, interval LARC becomes dominant only when pregnancy rates with an IUD
or implant in place are higher than 40 to 56%. Prospective and post marketing surveillance
reports show that LARC methods consistently have failure rates of less than 1%.
The pregnancy rate associated with other methods of birth control (used when no
IUD or implant is placed postpartum) also affect the robustness of the model to the base
case results. Interval LARC becomes the strategy of choice when this rate is less than 3 to
12%. In this study, this weighted rate was driven largely by no method use (which has a
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failure rate of up to 85%), based on the frequency distribution of contraceptive use by the
general population of reproductive aged women in the US (Guttmacher 2015).
The cost of immediate LARC initiation is also important to consider when using
our models. As long as the costs of insertion is less than $3,000 when QALYs are used as
the effectiveness measure and less than $10,000 in estimating unintended pregnancies
prevented, immediate postpartum LARC remains less costly and more effective.
The results of the sensitivity analyses emphasizes advantages of placing LARC
immediately postpartum compared to interval insertion, given the high loss to follow-up
in this population of postpartum women and the improbable values needed for birth
control pregnancy rates in order for it not to be cost effective. PSA results using Monte
Carlo simulation also show that the models were consistently cost effective, about 95% of
alternative models generated. The immediate postpartum period provides the perfect
opportunity to initiate LARC methods.

Application to the New Mexico population
Applying the marginal cost effectiveness value of immediate postpartum LARC
to population estimates in New Mexico gives a bigger picture of its societal impact. As
seen in the review of UNMH births from 2010-2012, an average of 3,200 women were
medically eligible to receive the IUD and implant per year. When followed during the
postpartum period, only 46% show up for a follow up visit. Although a number of other
factors can account for this, this value is lower than the parameter used in the models or
in previous reports.
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Private insurance costs specific to the women from New Mexico show potential
cost saving of $800,000 per year from improvements in quality of life and prevention of
unintended pregnancies. Similarly, coverage of the uninsured population with immediate
postpartum LARC can lead to cost saving of up to $1M. These findings could be used to
support policy changes that expand LARC coverage to these populations. Since the
financial benefit of immediate insertion does not accrue directly to the hospital most
hospitals are unlikely to provide LARC devices for insertion immediately after birth
(IUD) or prior to discharge (implant) unless they are confident they will be reimbursed by
third party payers.

Study limitations
1.

As with other cost effectiveness studies on LARC, the clinical inputs used in the

model were based largely on observational studies of fair quality and with a few
randomized clinical trials (RCTs). However, the prospective cohorts in these studies were
highly generalizable (Grimes, Lopez 2010).
2.

The study did not include comparisons of immediate/interval IUD initiation with

delayed postpartum insertion, which encompasses the time beyond 10 minutes of
placental delivery and up to less than 6 weeks postpartum. The reason for this exclusion
is two-fold. One, this practice is not popular in the state and two, there is limited research
within this timing strategy, except for the first 48 hours after delivery. These few studies
indicate that the IUD expulsion rates for this time period are even higher than immediate
insertion (Grimes, Lopez 2010).
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3. Estimates for utility values were taken from a convenience sample of women from a
previous study (Sonnenberg, Burkman 2004). Although sensitivity analysis show
robustness of the models to these parameters with use of values from a cross sectional
study of women (Schwarz, Smith 2008), it is recommended that population estimates be
conducted and sought out.

The results of this study emphasizes the societal benefits of immediate postpartum
LARC over interval insertion. Despite increased expulsion rates for the IUD and bleeding
irregularities leading to removal for the implant, the strategy of immediate insertion
remains the less costly and more effective alternative. This study is also innovative
because it is the first to look at both forms of LARC in the immediate postpartum period
and considered direct non-medical and indirect costs, which were often overlooked in
previous studies. These results have implications in patient counselling, as well as in
expanding LARC coverage. Importantly, the decision models created can be adopted to
estimate national data sets, as well as US states that provide no immediate postpartum
LARC insurance coverage.
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Appendix
De-identified data set for defining study population

1. Number of women in 2010, 2011 and 2012 who were eligible for immediate
Postplacental Mirena (levonorgestrel-containing) IUD
This was determined by getting the number of women who were admitted at
UNMH for labor and delivery (CPT codes based on vaginal/cesarean/vaginal-aftercesarean delivery 59409, 59410, 59514, 59515, 59612 and 59614) minus the patients who
(aside from being pregnant) were diagnosed with*-a. Chorioamnionitis (ICD9 code 658.41), puerperal sepsis (ICD9 670.02, 670.12
and 670.22)
b. Postpartum hemorrhage (ICD9 code 666.14 and 666.04), Cervical and high
vaginal laceration (ICD9 665.30 and 665.40)
c. Third degree laceration (ICD9 code 664.21 and 59300); for c and d, the CPT for
the mode of delivery has a modifier -22 attached
d. Fourth degree laceration (ICD9 code 664.31)
e. Systemic lupus erythematosus (ICD9 code 710.0)
f. Hepatocellular adenoma (ICD9 code 573.9)
g. Malignant liver hepatoma (ICD9 155.0, 155.2 and 197.7)
h. Breast cancer (ICD9 174.0 to 174.9, 198.81, 233.0)
i. Sexually transmitted infections (gonorrhea and chlamydia) complicating delivery
(ICD9 647.11 and 647.21)
j. AIDS (ICD9 042)
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k. Pelvic tuberculosis complicating pregnancy (ICD9 647.31)
l. Complicated Organ transplants (ICD9 code 996.8)

2. Number of women in 2010, 2011 and 2012 who were eligible for immediate
Postplacental Paragard (Copper-containing) IUD
This was determined by getting the number of women who were admitted at
UNMH for labor and delivery (CPT codes based on vaginal/cesarean/vaginal-aftercesarean delivery 59409, 59410, 59514, 59515, 59612 and 59614) minus the patients who
(aside from being pregnant) were diagnosed with*-a. Chorioamnionitis (ICD9 code 658.41), puerperal sepsis (ICD9 670.02, 670.12 and
670.22)
b. Postpartum hemorrhage (ICD9 code 666.14 and 666.04), Cervical and high
vaginal laceration (ICD9 665.30 and 665.40)
c. Third degree laceration (ICD9 code 664.21 and 59300); for c and d, the CPT for
the mode of delivery has a modifier -22 attached
d. Fourth degree laceration (ICD9 code 664.31)
e. Systemic lupus erythematosus (ICD9 code 710.0) with coagulation problems
(ICD9 649.31 and 666.31)
f. Sexually transmitted infections (gonorrhea and chlamydia) complicating delivery
(ICD9 647.11 and 647.21)
g. AIDS (ICD9 042)
h. Pelvic tuberculosis complicating pregnancy (ICD9 647.31)
i. Complicated Organ transplants (ICD9 code 996.8)
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3. Number of women in 2010, 2011 and 2012 who were eligible for immediate
postpartum contraceptive implant
Again, this was determined by getting the number of women who were admitted
at UNMH for labor and delivery (CPT codes based on vaginal/cesarean/vaginal-aftercesarean delivery 59409, 59410, 59514, 59515, 59612 and 59614) minus the patients who
(aside from being pregnant) were diagnosed with*—
a. Systemic lupus erythematosus (ICD9 code 710.0)
b. Breast cancer (ICD9 174.0 to 174.9, 198.81, 233.0)
c. Hepatocellular adenoma (ICD9 code 573.9)
d. Malignant liver hepatoma (ICD9 155.0, 155.2 and 197.7)

4. For each of the populations in #’s 1, 2 and 3, their frequency distribution in terms of
race, ethnicity, age (13 to 18 y/o versus 19 years old and above), and financial class and
insurance plans. Among those who are self-pay and indigent, how many of them have
PENDING EMSA at the time of discharge from the Mother Baby Unit or the OB Special
Care/High Risk Maternity.

5.

For each of the populations in #’s 1, 2 and 3, what is the average number of prenatal

visits (hospital/clinic encounters) and how many of them actually showed up for the
standard postpartum check-up (based on hospital/clinic encounter).

* The exclusion criteria were determined based on categories 3 and 4 (3 = A condition for
which the theoretical or proven risks usually outweigh the advantages of using the method
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and 4 = A condition that represents an unacceptable health risk if the contraceptive method
is used.) of the U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Adapted
from the World Health Organization Medical Eligibility Criteria for Contraceptive Use,
4th edition for the particular birth control method.
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